17th World ADC London Summit

Memo

As ADCs continue to redefine the standard of care in oncology, breakthrough clinical readouts, expanding approvals in earlier treatment settings, and a wave of landmark dealmaking have cemented ADCs as one of biopharma's most sought-after areas of investment. From Novartis' billion-dollar technology partnership with Myricx Bio to Gilead's acquisition of Tubulis, the industry's leading players are racing to secure differentiated linker-payload technologies, unlock novel targets, and develop the next generation of transformative ADC therapies for patients with hard-to-treat cancers. Returning as Europe's largest and longest-standing annual meeting for the ADC community, the 17th World ADC London returns in March as the definitive week to benchmark against industry leaders, validate internal strategies, forge strategic partnerships, and shape the future of ADC development. Bringing together 700+ senior leaders from biopharma, biotech, academia, clinical research, investment, and solution providers, this is where the brightest minds and most innovative companies converge to accelerate progress across the field. Featuring five streams of end-to-end content spanning discovery, preclinical and translational development, clinical lessons, process and analytical development, and manufacturing and supply chain, the 2027 agenda is curated to spotlight next-generation conjugate design, strategies to overcome resistance mechanisms, and the latest innovations accelerating ADCs towards clinical validation and earlier lines of treatment. As investment accelerates and competition for differentiated ADC technologies intensifies, this is the must-attend forum for the European and global ADC community to uncover breakthrough insights, benchmark against industry leaders, validate internal strategies, forge strategic partnerships, and gain the market intelligence needed to shape the next wave of ADC innovation. Whether you're racing to develop the next blockbuster beyond Enhertu, overcome resistance mechanisms, unlock novel targets, or bring differentiated ADCs to patients faster, World ADC London is your annual opportunity to stay ahead of the trends, technologies, and partnerships defining the future of the field. URLs:Tickets: https://go.evvnt.com/3843841-2?pid=5569Brochure: https://go.evvnt.com/3843841-3?pid=5569 Date and Time: Monday, 08 March 2027 at 08:00 - Thursday, 11 March 2027 at 16:00 Venue details: Novotel London West, 1 Shortlands Hammersmith International Ctre, London, England, W6 8DR, United Kingdom Category: Conferences Prices:Drug Developer Pricing - Conference + Seminar Day + Workshop Day: GBP 4920.00,Drug Developer Pricing - Conference + Seminar/Workshop Day: GBP 3890.00,Drug Developer Pricing - Conference Only: GBP 2860.00,Academic Pricing - Conference + Seminar Day + Workshop Day: GBP 4060.00,Academic Pricing - Conference + Seminar Day/Workshop Day: GBP 3230.00,Academic Pricing - Conference Only: GBP 2400.00,Service Provider Pricing - Conference + Seminar Day + Workshop Day: GBP 6880.00,Service Provider Pricing - Conference + Seminar/Workshop Day: GBP 5310.00,Service Provider Pricing - Conference Only: GBP 3740.00 Speakers: Alireza Tafazzol, Senior Scientist, AbbVie, Alan Russell, Vice President, Research and Head, R and D Technology and Innovation, Amgen, Dragan Grabulovski, Chief Executive Officer, Araris Biotech, David Illescas, Clinical Investigator, Arrixaca University Hospital, Elena de Orbe, Associate Principal, Computational Chemist, AstraZeneca, Tingting Cui, Associate Director, AstraZeneca, Osama Charhrour, Principal Scientist - New Modalities, AstraZeneca, Yu-Shin Hsu, Senior Research Analyst, Beacon Intelligence, Javad Shahidi, Senior Vice President, Head of Biotech Unit and Development Innovation, BeOne Medicines, Rakesh Dixit, President and Chief Executive Officer, Bionavigen Oncology, Yuan-An (Angus) Liu, Director Protein and ADC Drug Product, BioNTech, Evelyn Fahrenkrug, Global Commercial Head Oncology Pipeline, Boehringer Ingelheim, Wim Dokter, Chief Scientific Officer, Byondis, Jeremy Sauer, Vice President, Strategy, Callio Therapeutics, Charles Dumontet, Deputy Director and Investigator, Cancer Research Centre of Lyon, Giorgio Massimini, Chief Medical Officer, CanWell Pharma, Hong Zebger-Gong, Senior Medical Director, Global Oncology Clinical Development, Daiichi Sankyo, Leo Marx, Head of ADC Research and Technologies, Debiopharm, Jesús Fuentes Antrás, Medical Oncologist and Clinical Investigator, Hospital Universitario Quirónsalud Madrid, Jerome Boyd-Kirkup, Chief Scientific Officer and Co-Founder, Hummingbird Bioscience, Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Scott Lesley, President and Chief Scientific Officer, InduPro, Min Hu, Senior Vice President, Oncology Discovery, Innovent Biologics, Kurt Pike, Senior Director, Discovery Product Development and Supply (DPDS) External Innovation, Johnson and Johnson, Eugenio Cardenal Virgil, Associate Director Regulatory Affairs CMC, Johnson and Johnson, Matthew Sender, Director and ADC Project Lead, LigaChem Biosciences, Mike Seganish, Distinguished Scientist and Executive Director, Scientific Discovery, Merck and Co, Robert Andrews, ADC and Conjugate Patent Strategy (European Patent Attorney), Mewburn Ellis LLP, Valerie Vanhooren, Chief Executive Officer, Ona Therapeutics, Christian Rohlff, Chief Executive Officer, Oxford Biotherapeutics, Kevin Hamblett, Senior Director, ADC Pharmacology, Pfizer, Alain Beck, Senior Director, Biologics CMC Developability, Pierre Fabre, Nicola Beltraminelli, ADC Bioprocess Expert, Pierre Fabre, John Lambert, Consultant and Honorary Professor, Queen's University Belfast, Floriana Cremasco, Senior Scientist, Roche, Ines Grazina de Matos, Principal Scientist, Roche, Samuel Murphy, Chief Executive Officer, Salubris Biotherapeutics, Marc Robillard, Co-Founder and Chief Scientific Officer, Tagworks Pharmaceuticals, Harold Keer, Chief Medical Officer, Taiho Oncology, Greg Thurber, Professor, Chemical and Biomedical Engineering, University of Michigan, Ali Salanti, Co-Founder and Chief Executive Officer, VAR2 Pharmaceuticals, Tobias Gustavson, Senior Director, Bioconjugation and CMC, VAR2 Pharmaceuticals